FALL 2019
Solve M.E. Grows ME/CFS Research with Seven NEW Studies SOLVE M.E.’S RAMSAY GRANT
mune response that could be driving
PROGRAM provides pilot funding
immune dysfunction in ME/CFS.
for investigative studies into the symptoms and underlying causes of
Possible class II MHC deficiency
ME/CFS. Since 2016, the Ramsay
in patients Impact with ME/CFS
Program has successfully attracted new scientists to the field and kept
Bruno Paiva, PhD, (University of
them engaged. Ramsay funding
Navarra) is an expert researcher
allows researchers to generate pre-
in immunology and diseases of the
liminary data and refine hypotheses
blood. This is his first study in ME/
for further research, providing a key
CFS. Working with six multidisci-
bridge to pursue larger grants.
plinary co-Investigators, Dr. Paiva
Solve M.E. will fund seven stud-
will investigate if inherent defects
ies in 2019; welcoming over 30
in class II molecules of the major
investigators and collaborators,
histocompatibility (MHC)—a specific
including a number of early career
immune system pathway founda-
stage scientists. Over half of these
tional to your body’s defense—is
research teams include a Principal
driving ME/CFS symptoms for a
Investigator (PI) leading an ME/CFS
subgroup of patients. Decreased
study for the first time. Learn more
expression of these molecules would
about the exciting projects that will
be consistent with previous reports
unfold over the next year and meet the researchers behind them at
» to page 4
INSIDE
www.solvecfs.org. Altered T cells in ME/CFS that play a key role in tailoring Liisa Selin, PhD, is a University
the body’s immune response. The
of Massachusetts Medical School
researchers previously identified
researcher with deep knowledge of
elevated numbers of a subset of T
immune defense against viruses.
cells in blood samples from people
Dr. Selin and her co-PI, Anna
with ME/CFS. This study is designed
Gil, PhD, will examine the role of
to examine whether these cells re-
specific immune cells called T cells
flect a specific infectious or autoim-
2
Solve M.E. This Quarter
5
Positive Forecast for ME/CFS Federal Funding in 2020
7
Interview with NANDS Working Group Chair Dr. Steve Roberds
8
Patient Voices
9
Solve M.E. Answers Reader Questions
10 Your Support Makes an Impact 11 Reflections from Solve M.E. Leadership